GRF-containing lyophilized pharmaceutical compositions
View Patent ↗Human growth hormone factor (GFR) containing pharmaceutical compositions are described, and more precisely, lyophilized compositions of hGRF stabilized by means of saccharose.
1. A product which is a vial containing a pharmaceutical composition consisting of a lyophilized mixture of 3 to 10 mg/vial of human growth releasing factor (hGRF), 20.5 to 68.4 mg/vial of saccharose, and a buffering agent in an amount sufficient such that the pH is 4 to 6 when said lyophilized mixture is reconstituted in a solvent or solution.
2. The product according to claim 1 wherein the pharmaceutical composition contains 3 mg/vial of hGRF and 20.5 mg/vial of saccharose.
3. The product according to claim 2 in which the hGRF is recombinant hGRF.
4. The product according to claim 2 , wherein the vial is hermetically closed in a sterile condition, and is suited for a storage before use and for reconstitution of the mixture into a solvent or into a solution for injectables.
5. The product according to claim 1 , wherein the pharmaceutical composition contains 10 mg/vial of hGRF and 68.4 mg/vial of saccharose.
6. The product according to claim 5 in which the hGRF is recombinant hGRF.
7. The product according to claim 5 , wherein the vial is hermetically closed in a sterile condition, and is suited for a storage before use and for reconstitution of the mixture into a solvent or into a solution for injectables.
8. The product according to claim 1 , wherein the vial is hermetically closed in a sterile condition, and is suited for a storage before use and for reconstitution of the mixture into a solvent or into a solution for injectables.
9. The product according to claim 1 in which the hGRF is recombinant hGRF.